The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
11-Feb-25
$320 million (AUD value)
Target:
Pacific Smiles Group
Acquiror:
Genesis Capital
Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover
23-Jan-25
$150 million
Target:
D-Wave Quantum
Advised D-Wave Quantum, a leader in quantum computing systems and services, on its $150mm at-the-market equity offering program
13-Nov-24
Pending
Undisclosed
Target:
Centogene GmbH
Acquiror:
Charme Capital Partners
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
04-Oct-24
Pending
Undisclosed
Target:
Radio Frequency Components Business of Renesas Electronics Corporation
Acquiror:
CG Power and Industrial Solutions
Exclusive advisor to Renesas, a global provider of microcontrollers, combining expertise in embedded processing, analog, power and connectivity to deliver complete semiconductor solutions
09-Sep-24
Undisclosed
Target:
Pixelligent Technologies
Acquiror:
Henkel Corporation
Advised Pixelligent Technologies, a developer and manufacturer of nanocrystal material used in consumer electronic devices, on a significant strategic investment from Henkel Corporation, a publicly traded (FWB: HEN) German multinational chemical and consumer goods company
24-Jul-24
Undisclosed
Target:
INX Software
Acquiror:
Accel-KKR
Advised Tanarra Capital, leading diversified alternative asset investment firm in Australia, on its sale of INX Software, leading end-to-end workforce management and EHS software provider for high-risk, complex and remote businesses, to Accel-KKR
20-Feb-24
Pending
$185 million
Target:
myHomecare Group
Acquiror:
Australian Unity
Advising Australian Unity on its acquisition of myHomecare Group
18-Sep-23
Pending
Undisclosed
Target:
Central nervous system (CNS) portfolio from Sanofi
Acquiror:
Pharmanovia
Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
05-Oct-21
$175 million
Target:
Kao Data Ltd
Acquiror:
Infratil Ltd
Advised Kao Data Ltd, which is jointly owned by Legal & General Group PLC and Noé Group subsidiary Hockham, on raising an initial £120m-£130m growth capital commitment from Infratil Ltd with the objective of creating a £500m data centre platform
05-Aug-21
$2 billion
Target:
Score Media and Gaming, Inc.
Acquiror:
Penn National Gaming, Inc.
Advising the Board of Directors of Score Media and Gaming (“theScore”), a leading digital media and sports betting and technology company, regarding the acquisition of theScore by Penn National Gaming
10-May-21
$280 million
Target:
Photon Control
Acquiror:
MKS Instruments
Advising MKS, a global provider of instruments, systems, subsystems and process control solutions, on the acquisition of Photon Control, a Canadian manufacturer of fiber optic measurement solutions used in semiconductor wafer fabrication
24-Feb-21
Undisclosed
Target:
Resource Optimization Software Business Area of Net Insight
Acquiror:
Xytech Systems Corporation
Advising Net Insight AB, a global leader in media networks, on the divestment of its resource optimization software business area, doing business as “ScheduALL” to Xytech Systems Corporation
28-Oct-20
Undisclosed
Target:
Easton Investments Limited
Acquiror:
HUB24 Limited
Advising HUB24 Limited (ASX: HUB), a leading specialist investment platform provider, on its proposed acquisition of up to 40% in Easton Investments Limited (ASX: EAS), a leading provider of wealth and accounting solutions. The transaction also included the divestment of HUB24’s subsidiary, Paragem, to Easton
22-Sep-20
$NA
Target:
VX Fiber
Acquiror:
AMP Capital
Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
23-Mar-20
$68 million
Target:
Abacus Health Products, Inc.
Acquiror:
Charlotte’s Web Holdings, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
17-Dec-19
~$35 million
Target:
Sye business area of Net Insight AB
Acquiror:
Amazon.com, Inc.
Advised Net Insight AB, a global leader in media networks, on the sale of Sye, a market-leading true live “over-the-top” (OTT) technology for low-latency live streaming, to Amazon.com, Inc.
26-Apr-19
$1.0 billion
Target:
T5 Data Centers Strategic Partnership
Acquiror:
QuadReal
Advised T5 Data Centers, a leading national data center owner and operator, on the creation of a fully integrated platform with QuadReal Property Group to develop, acquire and operate data centers via a $1.0 billion investment from QuadReal
19-Dec-18
$NA
Target:
Starpharma Holdings Limited, patented VivaGel BV® product
Acquiror:
ITF Pharma, US subsidiary of Italfarmaco S.p.A.
Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
24-Oct-18
$41 million
Target:
TeePublic
Acquiror:
Redbubble
Advised Redbubble, a global online independent artist community and marketplace, on the acquisition of TeePublic, a similar online platform, and associated A$61 million equity raising
10-Sep-18
$100 million
Target:
Montserrat Day Hospital Group
Acquiror:
Primary Health Care
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
15-Aug-18
$3.9 billion
Target:
Common shares and common share purchase warrants in Canopy Growth
Acquiror:
Constellation Brands
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.